<DOC>
	<DOCNO>NCT00861965</DOCNO>
	<brief_summary>This phase I/II clinical investigation design determine safety anti-tumor effect intravenous administration experimental immunotherapy drug , call AlloStim . The active ingredient AlloStim living , human immune cell differentiate expand outside body . Because AlloStim require HLA match , evaluate alternative allogeneic bone marrow/stem cell transplantation .</brief_summary>
	<brief_title>Bioengineered Allogeneic Immune Cells ( AlloStim ) Not Requiring HLA Donor Match Alternative Allogeneic Transplant Blood Cancers</brief_title>
	<detailed_description>AlloStim test determine might elicit anti-tumor mechanism occur allogeneic bone marrow/stem cell transplant ( BMT ) procedure , without toxicity associate graft vs. host disease ( GVHD ) . In allogeneic BMT setting , patient first condition weaken immune system order enable engraftment allogeneic donor cell . Patients require matched-tissue donor set order enable engraftment also minimize GVHD toxicity . While allogeneic BMT potentially curatve therapy , treatment-related mortality , mostly relate GVHD toxicity , high . This toxicity limit clinical utility procedure . AlloStim test determine might less toxic alternative allogeneic BMT . In protocol , patient condition chemotherapy prior treatment . Therefore , allogeneic cell AlloStim expect reject patient 's immune system within 24-48 hour infusion .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Histologically confirm hematological malignancy 1 follow type : Acute Myeloid Leukemia ( AML ) meeting follow criterion : Relapsed primary refractory disease ≤ 10 % blast peripheral blood ≤ 20 % blast bone marrow . Acute Lymphoblastic Leukemia ( ALL ) meeting follow criterion : Relapsed primarily refractory disease ≤ 10 % blast peripheral blood ≤ 20 % blast bone marrow Chronic Myeloid Leukemia ( CML ) * inadequate response imatinib meeting 1 follow criterion : Second subsequent chronic phase Accelerated phase [ *Patients CML blast crisis ( &gt; 30 % promyelocytes myeloblasts bone marrow ) eligible ] NonHodgkin 's Lymphoma ( NHL ) include Mantle Cell Lymphoma ( MCL ) meet 1 follow criterion : Primary refractory disease refractory relapse Relapsed disease autologous stem cell transplantation Chemosensitive relapse disease without CR standard salvage therapy AND option autologous stem cell transplantation due blood marrow involvement failure harvest sufficient autologous stem cell . Chronic Lymphocytic Leukemia ( CLL ) meeting follow criterion : Stage III IV disease Refractory fludarabine , Rituxan® Campath® refuse Multiple Myeloma ( MM ) meet 1 follow criterion : Primary refractory disease refractory relapse Relapsed disease autologous stem cell transplantation Hodgkin 's Disease Relapsed prior autologous transplant 2 combination chemotherapy regimens ineligible autologous stem cell transplant . EBV driven lymphoproliferative disorder immunocompetent patient progress despite standard therapy , include : Tcell NonHodgkin 's Lymphoma Burkitt 's Lymphoma EBV+ Hodgkin 's Disease Ability comprehend investigational nature study provide inform consent . Measurable evaluable disease Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 . Age 18 year old Expected survival 6 month longer No radiation chemotherapy previous 2 week No immunotherapy previous 4 week Absence active infection within 2 week Adequate hepatic function , total bilirubin level le 1.2 time upper limit normal ( ULN ) aspartate alanine aminotransferase level less 2.5 time ULN prior infusion Adequate bone marrow function define white blood cell count least 2 x 109/L ( 2000/µL ) , absolute neutrophil count least 1 x 109/L ( 1000/µL ) , hemoglobin level least 80 g/L ( 8.0 g/dL ) , platelet count least 50 x 109/L ( 50,000/µL ) priot infusion . Patients transfusion growth factordependent allow , provide value could achieve transfusion . Adequate cardiovascular function define ischemia , new conduction system abnormality , class 3 4 New York Heart Association congestive heart failure , myocardial infarction previous 6 month . A ≥45 % leave ventricular ejection fraction ( LVEF ) require previous 6 month . Adequate kidney function define serum creatinine level 1.5 mg/dL less , estimate creatinine clearance level least 60 mL/min prior infusion . Adequate lung function define pulse oxymetry great equal 92 % room air prior infusion , DLco≥50 % , FEV1 FVC ≥50 % within 2 week No know allergy murine product HAMA test result within normal limit No know allergy bovine product No pregnancy breast feeding No known human immunodeficiency virus ( HIV+ ) No seropositivity active viral hepatitis ( HBV+ , HCV+ ) No prior allogeneic transplant ( cell organ ) No serious concomitant medical psychiatric condition could interfere treatment . No EBVinduced lymphoma associate immunosuppression , include patient iatrogenic immunodeficiency ( organ transplant ) HIVrelated immunodefiency . No chronic myelogenous leukemia blast crisis . No myelodysplastic syndrome refractory anemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Multiple Myeloma</keyword>
</DOC>